Ligand closes acquisition of XOMA Royalty for $39 per share cash

Ligand Pharmaceuticals has completed its acquisition of XOMA Royalty, purchasing all outstanding common shares. Shareholders received $39 per share in cash and one non-transferable Contingent Value Right (CVR) per share, tied to 75% of net proceeds from certain pending litigation. Following the closing, XOMA Royalty's stock ceased trading on Nasdaq.

Ligand Pharmaceuticals completed its acquisition of XOMA Royalty, buying all outstanding common shares. * Stockholders received USD 39 per share in cash under terms announced April 27, 2026. * Holders also received one non-transferable CVR per share tied to 75% of net proceeds from certain pending litigation. * XOMA Royalty common stock stopped trading on Nasdaq following the closing. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XOMA Royalty Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607140900PRIMZONEFULLFEED9761821) on July 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)